Home example 2 - Pharmamarketeer

technologie

New medical imaging device could help cut time and cost of procedures

Researchers have completed a successful clinical trial, managing to detect and image radioactive tracers used in PET and in SPECT scans at the same time, with the hope of enabling doctors to scan patients for...

News-Medical.Net

4 x gelezen

onderzoek

Reprieve Cardiovascular announces positive results from first?in?human trial with PVM System for AHF

Reprieve Cardiovascular: Reprieve Cardiovascular, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), announced the results of the...

Pharma Biz

4 x gelezen

onderzoek

Coronaprik wordt ook mogelijk voor gezonde kinderen van 5 tot 12

Coronaprik wordt ook mogelijk voor gezonde kinderen van 5 tot 12 Ook ouders met gezonde kinderen tussen de 5 en 12 jaar oud krijgen de mogelijkheid om hun kind tegen corona te laten vaccineren. Het demissionaire kabinet...

Redactie

4 x gelezen

wet- en regelgeving

AbbVie submits applications for treatment of chronic disease

Treatment of chronic disease AbbVie has announced the submission of applications seeking the approval of upadacitinib, (RINVOQ®, 15 mg once daily) for the treatment of adults with active non-radiographic axial...

InPharm.com

4 x gelezen

marketing

Why brands are seeking more nuanced, humanized audience segmentation for campaign success

Why brands are seeking more nuanced, humanized audience segmentation for campaign success Laura Goldstone, senior director, communications and branding strategy, AdDaptive Intelligence Despite the hard work brands put...

digiday.com

4 x gelezen

overig

NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma

Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered Type II anti-CD20 monoclonal antibody will now be available on the NHS when used in...

Pharmafile

4 x gelezen

overig

Ontruzant launches to become first Herceptin biosimilar available in the UK

Ontruzant, the biosimilar version of Herceptin (trastuzumab) originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK, becoming the first biologic copycat version of Roche’s blockbuster...

Pharmafile

4 x gelezen

wet- en regelgeving

Mundipharma’s Neulasta biosimilar approved in EU

Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European Commission. The decision was driven by a “a robust regulatory...

InPharm.com

4 x gelezen

farma-industrie

Roche appoints William (Bill) Anderson as CEO from January 01, 2019

Roche announced that Daniel O’Day, CEO Roche Pharmaceuticals and member of the corporate executive committee, will be stepping down from his role as of 31 December 2018.

Pharma Biz

4 x gelezen

onderzoek

New bacteria-based drug delivery system could radically expand cancer treatment options

An interdisciplinary team of three Virginia Tech faculty members affiliated with the Macromolecules Innovation Institute has created a drug delivery system that could radically expand cancer treatment options.

News-Medical.Net

4 x gelezen

Latest articles

New medical imaging device could help cut time and cost of procedures

Reprieve Cardiovascular announces positive results from first?in?human trial with PVM System for AHF

Coronaprik wordt ook mogelijk voor gezonde kinderen van 5 tot 12

AbbVie submits applications for treatment of chronic disease

Why brands are seeking more nuanced, humanized audience segmentation for campaign success

NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma

Ontruzant launches to become first Herceptin biosimilar available in the UK

Mundipharma’s Neulasta biosimilar approved in EU

Roche appoints William (Bill) Anderson as CEO from January 01, 2019

New bacteria-based drug delivery system could radically expand cancer treatment options

Wekelijkse highlights per e-mail

Algemene informatie